Moleculin Biotech (NASDAQ:MBRX) Given “Buy” Rating at HC Wainwright

Moleculin Biotech (NASDAQ:MBRX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $8.00 target price on the stock.

MBRX has been the topic of a number of other research reports. Maxim Group cut shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. StockNews.com initiated coverage on Moleculin Biotech in a research report on Thursday, March 13th. They issued a “sell” rating for the company.

Moleculin Biotech Stock Performance

Moleculin Biotech stock traded down $0.04 during mid-day trading on Monday, reaching $1.05. The stock had a trading volume of 347,955 shares, compared to its average volume of 6,233,274. Moleculin Biotech has a one year low of $0.40 and a one year high of $6.23. The company has a 50-day moving average price of $1.36 and a two-hundred day moving average price of $2.02.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.